HONG KONG, Oct 9, 2025 – (ACN Newswire via SeaPRwire.com) – Everest Medicines today announced that the results of its Asian multicenter Phase III ENLIGHT UC study (ES101002) of etrasimod (VELSIPITY(R)) for the treatment of subjects with moderately to severely active ulcerative colitis (U […]